临床医学工程2024，Vol.31Issue(10)：1235-1236,2.DOI:10.3969/j.issn.1674-4659.2024.10.1235
替吉奥联合奥沙利铂对中晚期胃癌患者的治疗效果
Therapeutic Effect of Tegafur Combined with Oxaliplatin on Patients with Middle-Advanced Gastric Carcinoma
曹静 1郭玉霞 2王秀娟3
作者信息
- 1. 驻马店市第一人民医院肿瘤放疗科,河南驻马店 463000
- 2. 驻马店市第一人民医院肿瘤内科,河南驻马店 463000
- 3. 驻马店市第一人民医院介入科,河南驻马店 463000
- 折叠
摘要
Abstract
Objective To explore the clinical effect of tegafur combined with oxaliplatin in the treatment of patients with middle-advanced gastric carcinoma(GC).Methods A total of 65 patients with middle-advanced GC admitted to our hospital from August 2019 to August 2020 were selected and divided into group A(32 cases)and group B(33 cases)according to different treatment methods.Group A was treated with tegafur combined with oxaliplatin,and group B was treated with capecitabine combined with oxaliplatin.The clinical efficacy,gastrin(GAS)and survivin antibody levels,and toxic side effects were compared between the two groups.Results The total effective rate of treatment in group A was 68.75％,higher than 42.42％in group B(P＜0.05).After 4 cycles of treatment,the levels of serum GAS and survivin antibody in group A were lower than those in group B(P＜0.05).No significant difference was found in the incidences of nausea and vomiting,alopecia,liver and kidney injury,and leukopenia between group A and group B(P＞0.05).Conclusions Tegafur combined with oxaliplatin in the treatment of patients with middle-advanced GC has exact effect,which can obviously reduce the serum GAS and survivin antibody levels of patients,and does not significantly increase the occurrence risk of toxic side effects.关键词
中晚期胃癌/替吉奥/奥沙利铂/胃泌素/survivin抗体Key words
Middle-advanced gastric carcinoma/Tegafur/Oxaliplatin/Gastrin/survivin antibody分类
医药卫生引用本文复制引用
曹静,郭玉霞,王秀娟..替吉奥联合奥沙利铂对中晚期胃癌患者的治疗效果[J].临床医学工程,2024,31(10):1235-1236,2.
